Approval · Notice of Compliance 14099 · 2013
PREGABALIN: Notice of Compliance 14099
Issued February 14, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14099
- Date
- February 14, 2013
- Company
- Laboratoire Riva Inc.Blainville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Analgesic agent
- Canadian reference product
- LYRICA (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PREGABALIN | 02376946 | Cancelled Pre Market |
| PREGABALIN | 02376954 | Cancelled Pre Market |
| PREGABALIN | 02376962 | Cancelled Pre Market |
| PREGABALIN | 02376970 | Cancelled Pre Market |
| PREGABALIN | 02376989 | Cancelled Pre Market |
Medicinal ingredients
- PREGABALIN 25 MG per CAP
- PREGABALIN 50 MG per CAP
- PREGABALIN 75 MG per CAP
- PREGABALIN 150 MG per CAP
- PREGABALIN 300 MG per CAP